Brigatinib, a second-generation ALK inhibitor, outperformed crizotinib in the ALTA-1 study for PFS and health-related quality of life (QoL) in advanced ALK drug-naive ALK-positive non-small cell lung cancer. Here, ALK is linked to non-small cell lung carcinoma.